Search Result

Results for "

IRAK4 degrader

" in MedChemExpress (MCE) Product Catalog:

By Targets:	IRAK (34) AAK1 (1) Apoptosis (10) Autophagy (2) CCR (1) CDK (1) CXCR (1) Drug Intermediate (1) E3 Ligase Ligand-Linker Conjugates (2) Enolase (1) Ephrin Receptor (1) FGFR (1) Glucocorticoid Receptor (4) IFNAR (2) Interleukin Related (10) Itk (1) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (4) MAP4K (1) MELK (1) NF-κB (6) p38 MAPK (4) PROTAC Linkers (3) PROTACs (31) Reference Standards (2) TGF-β Receptor (4) TNF Receptor (3) Toll-like Receptor (TLR) (1) ULK (1) Wee1 (1)
By Research Areas:	Cancer (33) Inflammation/Immunology (20) Metabolic Disease (2) Neurological Disease (5)
Click Chemistry:	PROTAC Synthesis (1)

Inhibitors & Agonists

Click Chemistry

Targets Recommended: IRAK

Cat. No.	Nom du produit	Target	Áreas de investigación	Chemical Structure

HY-145483

KT-474 1 Publications Verification KYM-001; PROTAC IRAK4 degrader-7	PROTACs IRAK Apoptosis	Cancer
KT-474 (KYM-001; PROTAC IRAK4 degrader-7) is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL. KT-474 is a click chemistry reagent, containing an alkyne group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing azide groups .

HY-B1829A

Dexamethasone phosphate disodium Maximum Cited Publications 11 Publications Verification Dexamethasone 21-phosphate disodium	Glucocorticoid Receptor TGF-β Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
Dexamethasone phosphate (Dexamethasone 21-phosphate) disodium is a prodrug form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone phosphate disodium is produced by introducing a phosphate ester group at the 21-position of the Dexamethasone molecule, forming a salt with sodium ions, thereby significantly improving water solubility. Dexamethasone phosphate disodium inhibits LPS (HY-D1056)-induced degradation of IRAK-1 and IRAK-4, and blocks LPS-induced activation of TRAF6, p-TAK1 and p-JNK. Dexamethasone phosphate disodium inhibits the secretion of RANTES, TGF-β1 and NO, promotes the production of MIP-1α and IL-10, and blocks microglial migration. Dexamethasone phosphate disodium is almost completely converted to Dexamethasone in rat blood, and supports transdermal delivery via iontophoresis. Dexamethasone phosphate disodium can be used in research related to steroid-dependent ulcerative colitis, chemotherapy-induced vomiting, allergic asthma and acute colitis (inflammatory bowel disease) .

HY-153368

Zomiradomide KT-413	PROTACs IRAK NF-κB IFNAR	Cancer
Zomiradomide is an orally active PROTAC degrader for *IRAK4* (DC₅₀=6 nM), thereby inhibiting the NF-κB signaling pathway. Zomiradomide acts also as a molecular glue, recruiting Ikaros and Aiolos, and mediating their degradation (DC₅₀ for Ikaros is 1 nM), thereby activating the type I IFN signaling pathway . (Pink: target protein ligand PROTAC IRAK4 ligand-5 (HY-168311), Blue: E3 ligase ligand Thalidomide-4-Br (HY-W039116), Black: linker (HY-168313))

HY-129966

*PROTAC IRAK4* degrader-1** 1 Publications Verification	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-1 (compound I-210) is a Cereblon-based IRAK4 PROTAC. PROTAC IRAK4 degrader-1 is composed of IRAK4 ligand (red part) PROTAC IRAK4 ligand-1 (HY-129967), E3 ligase ligand (blue part) Pomalidomide (HY-10984), and PROTAC linker (black part) AM-Imidazole-PA-Boc (HY-129968) .

HY-41547

Thalidomide 4-fluoride Cereblon ligand 4; E3 ligase Ligand 4	Ligands for E3 Ligase Autophagy Apoptosis	Cancer
Thalidomide 4-fluoride (Cereblon ligand 4) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide 4-fluoride (Cereblon ligand 4) can be connected to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1 (HY-129966) .

HY-135382A

*PROTAC IRAK4* degrader-3**	PROTACs IRAK	Inflammation/Immunology
PROTAC IRAK4 degrader-3 is a PROTAC-induced *IRAK4* degrader based on von Hippel-Lindau .

HY-W087383

Thalidomide 5-fluoride	Ligands for E3 Ligase Autophagy Apoptosis	Cancer
Thalidomide 5-fluoride is a thalidomide-based Cereblon ligand used to recruit Cereblon protein. Thalidomide 5-fluoride can be linked to target protein ligands (e.g. *IRAK4) through a linker to form PROTAC molecules (e.g. PROTAC IRAK4* degrader-1). PROTAC IRAK4 degrader-1 caused <20%, >20-50%, and >50% IRAK4 protein degradation in OCI-LY-10 cells at concentrations of 0.01, 0.1, and 1 μM, respectively .

HY-153188

JNJ-1013	PROTACs Apoptosis IRAK	Cancer
JNJ-1013 is a potent and selective IRAK1 PROTAC degrader with an IC₅₀s of 72, 443, 1071 nM for IRAK1, IRAK4, VHL FP respectively. JNJ-1013 induces apoptosis and increases the expression of cleavaged PARP. JNJ-1013 decreases the expression IRAK1, p-IKBα, pSTAT3(Tyr705) (Pink: ligand for target protein (HY-138834); black: linker (HY-Y1760); Blue: E3 ligase ligand (HY-112078)) .

HY-148065

FMF-06-098-1	PROTACs Wee1 CDK AAK1 ULK MELK Itk IRAK Ephrin Receptor FGFR MAP4K p38 MAPK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .

HY-153673

*PROTAC IRAK4* degrader-8**	IRAK PROTACs	Cancer
PROTAC IRAK4 degrader-8 (Compound 2) is a PROTAC *IRAK4* degrader (IC₅₀: 15.5 nM). PROTAC IRAK4 degrader-8 degrades IRAK4 in THP-1 cells (DC₅₀: 1.8 nM)。PROTAC IRAK4 degrader-8 also inhibits L-6 production in human whole blood and LPS-induced human PBMC cells, with IC₅₀s of 246 nM and 2.2 nM respectively .

HY-148290

KTX-951	PROTACs IRAK	Cancer
KTX-951 is an orally active *IRAK4* and IMiD (Ikaros/Aiolos) substrates PROTAC degrader (K_d = 3.5 nM). KTX-951 has DC₅₀s of 13 nM, 14 nM and 13 nM for IRAK4, Ikaros and Aiolos, respectively. KTX-951 has IC₅₀ of 35 nM for OCl-Ly10 CTG. KTX-951 has antitumor activity.(Pink: IRAK4 ligand-12 (HY-48932); Black: Linker (HY-W382009); Blue: CRBN Ligand Pomalidomide (HY-10984)) .

HY-175022

*PROTAC IRAK4* degrader-13**	PROTACs IRAK Toll-like Receptor (TLR) Interleukin Related	Inflammation/Immunology
PROTAC IRAK4 degrader-13 (Degrader 1) is a selective *IRAK4* PROTAC degrader with DC₅₀s of 0.86 and 1.1 nM for monocytes and lymphocytes in PBMCs, respectively. PROTAC IRAK4 degrader-13 significantly induces TIR signal activation, and inhibits the expression of circulating proinflammatory cytokines in Imiquimod (HY-B0180) induced psoriasis mice model. PROTAC IRAK4 degrader-13 can be used for TLR- and IL-1R-driven driven neutrophilic inflammation diseases like hidradenitis suppurativa (HS) and atopic dermatitis (AD) research . Pink: IRAK4 ligand; Blue: E3 ligase ligand; Black: linker

HY-135382

*PROTAC IRAK4* degrader-2**	PROTACs IRAK	Inflammation/Immunology Cancer
PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC₅₀ in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC₅₀ of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs .

HY-175764

FIP22	PROTACs IRAK NF-κB p38 MAPK TNF Receptor Interleukin Related	Inflammation/Immunology
FIP22 is a potent and selective IRAK4 PROTAC degrader (HEK293T cells: DC₅₀ = 3.2 nM; THP-1 cells: DC₅₀ = 10.6 nM). FIP22 induces the ubiquitin-proteasome system by forming an IRAK4-FIP22-CRBN ternary complex (EC₅₀ = 12.63 nM), thereby potently blocking IRAK4-mediated NF-κB and MAPK signaling pathways. FIP22 can be used for the study of atopic dermatitis (Pink: IRAK4 ligand (HY-175765); Blue: CRBN ligand (HY-W087383); Black: Linker (HY-46871)) .

HY-148274

KTX-582	PROTACs IRAK Apoptosis	Cancer
KTX-582 is a potent *IRAK4* degrader with DC₅₀ values of 4 nM and 5 nM for IRAK4 and Ikaros, respectively. KTX-582 can induce apoptosis in MYD88 ^MT DLBCL, and is efficient to induce in vivo tumor regressions in lymphoma model .

HY-46871

3,9-Dimethyl-3,9-diazaspiro[5.5]undecane	PROTAC Linkers	Inflammation/Immunology
3,9-Dimethyl-3,9-diazaspiro[5.5]undecane is a rigid PROTAC linker can be used in the synthesis of PROTACs, such as FIP22 (HY-175764). FIP22 is a potent and selective IRAK4 PROTAC degrader with anti- atopic dermatitis activity .

HY-174455

APH02174	PROTACs IRAK Interleukin Related	Inflammation/Immunology
APH02174 is a highly selective and orally active IRAK4 PROTAC degrader with the DC₅₀ of 4.01 nM in THP-1 cells. APH02174 blocks inflammatory signals by inhibiting IL-6 release. APH02174 can be used for research on inflammatory conditions such as psoriasis vulgaris and rheumatoid arthritis .

HY-139316

*PROTAC IRAK4* degrader-5**	IRAK PROTACs	Cancer
PROTAC IRAK4 degrader-5 is a Cereblon-based *IRAK4* degrader extracted from patent US20190192668A1, compound I-171 .

HY-139315

*PROTAC IRAK4* degrader-4**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-4 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-127 .

HY-179094

PSP-0119	PROTACs IRAK NF-κB Enolase	Inflammation/Immunology Cancer
PSP-0119 is a highly efficient and effective PROTAC degrader targeting *IRAK4* (IC₅₀ = 2.83 nM). PSP-0119 can inhibit *IRAK4* kinase activity, NF-κβ activity, and IL-1β-induced IRAK4 phosphorylation. PSP-0119 degrades IRAK4 in FLT3-mutant AML cell lines, sparing FLT3-wild-type AML cells, FLT3-wild-type samples, and normal bone marrow. PSP-0119 downregulates alpha-enolase (eNOS) of MOLM-13 cells. PSP-0119 can be used for the study of Acute Myeloid Leukemia (AML) .

HY-75005

1-Boc-4-carboxymethyl piperazine	PROTAC Linkers	Cancer
1-Boc-4-carboxymethyl piperazine is a PROTAC linker. 1-Boc-4-carboxymethyl piperazine can be used in the synthesis of PROTACs (e.g. PROTAC IRAK4 degrader-12 (HY-168586)) .

HY-148276

KTX-497	PROTACs IRAK	Cancer
KTX-497 is an *IRAK4* PROTAC degrader with a DC₅₀ value of 3 nM. KTX-497 can be used for the research of oncology ^[1].(Pink:IRAK4 inhibitor (HY-150735); Black: linker; Blue: CRBN Ligand (HY-10984))

HY-142662A

*PROTAC IRAK3 degrade-1 formic*	PROTACs IRAK	Others
PROTAC IRAK3 degrader-1 formic is a potent and selective *IRAK3* degrader with a DC₅₀ of 0.002 μM. PROTAC IRAK3 degrader-1 formic induces proteasome-dependent degradation of *IRAK3* via ternary complex formation with *IRAK3* and CRBN. PROTAC IRAK3 degrader-1 formic can be used for cancer research .

HY-139317

*PROTAC IRAK4* degrader-6**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-6 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-172 .

HY-129967

PROTAC IRAK4 ligand-1	Ligands for Target Protein for PROTAC	Cancer
PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4 (IRAK4). PROTAC IRAK4 ligand-1 can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966) .

HY-168586

*PROTAC IRAK4* degrader-12**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-12 is a PROTAC based on Cereblon ligand, inducing a maximum degradation rate of IRAK4 of 108.46% in K562 cells with an IC₅₀ value of 4.87 nM ( Structure Note: Pink, IRAK4 inhibitor (HY-168611); Blue, E3 (HY-W733885); Black, linker (HY-168613)) .

HY-B1829AR

Dexamethasone phosphate disodium (Standard) Dexamethasone 21-phosphate disodium (Standard)	Glucocorticoid Receptor Reference Standards Interleukin Related TGF-β Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Dexamethasone phosphate (Dexamethasone 21-phosphate) disodium (Standard) is the analytical standard of Dexamethasone phosphate disodium (HY-B1829A). This product is intended for research and analytical applications. Dexamethasone phosphate (Dexamethasone 21-phosphate) disodium is a prodrug form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone phosphate disodium is produced by introducing a phosphate ester group at the 21-position of the Dexamethasone molecule, forming a salt with sodium ions, thereby significantly improving water solubility. Dexamethasone phosphate disodium inhibits LPS (HY-D1056)-induced degradation of IRAK-1 and IRAK-4, and blocks LPS-induced activation of TRAF6, p-TAK1 and p-JNK. Dexamethasone phosphate disodium inhibits the secretion of RANTES, TGF-β1 and NO, promotes the production of MIP-1α and IL-10, and blocks microglial migration. Dexamethasone phosphate disodium is almost completely converted to Dexamethasone in rat blood, and supports transdermal delivery via iontophoresis. Dexamethasone phosphate disodium can be used in research related to steroid-dependent ulcerative colitis, chemotherapy-induced vomiting, allergic asthma and acute colitis (inflammatory bowel disease).

HY-172590

LZ-07	PROTACs IRAK Interleukin Related TNF Receptor	Inflammation/Immunology
LZ-07 is a IRAK4 PROTAC degrader (DC₅₀ = 1.14 nM). LZ-07 leads to marked suppression of cytokines including IL-6, IL-1β, TNF-α, and IL-10 upon degradation of IRAK4. LZ-07 can be studied in research for autoimmune diseases (Pink: IRAK4 ligand (HY-172591); Blue: CRBN ligand (HY-34590); Black: linker (HY-B0149); CRBN ligand + linker: HY-172593) .

HY-175766

CRBN Ligand-Linker Conjugate 2	E3 Ligase Ligand-Linker Conjugates	Inflammation/Immunology
CRBN Ligand-Linker Conjugate 2 is a synthesized E3 ligand-linker conjugate that can be used for synthesis of PROTACs, such as FIP22 (HY-175764). FIP22 is a potent and selective IRAK4 PROTAC degrader with anti- atopic dermatitis activity .

HY-158758

*PROTAC IRAK4* degrader-10**	PROTACs IRAK	Inflammation/Immunology
PROTAC IRAK4 degrader-10 (compound 10) is an oral active PROTAC based on Cereblon ligand, and induces the degradation of IRAK4 with maximum degradation of 95.94% and the DC₅₀ of 7.68 nM in HEK293 cells (Sturcture Note:(Blue: Cereblon ligand, Black: linker；Pink: IRAK4 ligand) .

HY-158760

*PROTAC IRAK4* degrader-11**	PROTACs IRAK	Cancer
PROTAC IRAK4 degrader-11 (compound 15) is PROTAC based on Cereblon ligand, and induces the degradation of IRAK4 with maximum degradation of 96.25% and the DC₅₀ of 2.29 nM in HEK293 cells(Sturcture Note:(Blue: Cereblon ligand (HY-14658), Black: linker；Pink: IRAK4 inhibitor) .

HY-B1829

Dexamethasone phosphate Maximum Cited Publications 11 Publications Verification Dexamethasone 21-phosphate	Glucocorticoid Receptor TGF-β Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
Dexamethasone phosphate (Dexamethasone 21-phosphate) is a prodrug form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone phosphate is prepared by introducing a phosphate ester group to the hydroxyl group at position 21 of the Dexamethasone molecule. Dexamethasone phosphate inhibits LPS (HY-D1056)-induced degradation of IRAK-1 and IRAK-4, and blocks LPS-induced activation of TRAF6, p-TAK1 and p-JNK. Dexamethasone phosphate inhibits the secretion of RANTES, TGF-β1 and NO, promotes the production of MIP-1α and IL-10, and blocks microglial migration. Dexamethasone phosphate is almost completely converted to Dexamethasone in rat blood, and supports transdermal delivery via iontophoresis. Dexamethasone phosphate can be used in research related to steroid-dependent ulcerative colitis, chemotherapy-induced vomiting, allergic asthma and acute colitis (inflammatory bowel disease) .

HY-145483A

KT-474 hydrochloride 1 Publications Verification KYM-001 hydrochloride; PROTAC IRAK4 degrader-7 hydrochloride	PROTACs IRAK Apoptosis	Cancer
KT-474 (KYM-001; PROTAC IRAK4 degrader-7) hydrochloride is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL. KT-474 is a click chemistry reagent, containing an alkyne group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing azide groups .

HY-179095

UR241-2	Ligands for Target Protein for PROTAC IRAK NF-κB p38 MAPK	Cancer
UR241-2 is an *IRAK4* inhibitor. UR241-2 suppresses IL-1–induced *IRAK1/4* signaling, NF-κβ activation, and phosphorylation of p65 and p38. UR241-2 selectively inhibits leukemia stem cell clonogenicity. UR241-2 can serve as a ligand for target proteins for PROTAC, facilitating the development and design of PROTAC degraders for IRAK4. UR241-2 can be used in the research of acute myeloid leukemia .

HY-148277

KTX-612	PROTACs IRAK	Cancer
KTX-612 is an orally active *IRAK4* PROTAC degrader with a DC₅₀ value of 7 nM. KTX-612 can be used for the research of oncology ^[1].(Pink:IRAK4 inhibitor (HY-150735); Black: linker; Blue: CRBN Ligand (HY-10984))

HY-181708

*PROTAC IRAK4* degrader-14**	PROTACs IRAK TNF Receptor IFNAR Interleukin Related CXCR CCR	Inflammation/Immunology
PROTAC IRAK4 degrader-14 is an orally active *IRAK4* PROTAC degrader with a DC₅₀ of 2.4 nM. PROTAC IRAK4 degrader-14 inhibits proinflammatory responses in multiple cell types including T cells, monocytes and keratinocytes. PROTAC IRAK4 degrader-14 is applicable to research related to psoriasis .

HY-142662

*PROTAC IRAK3 degrader-1*	PROTACs IRAK	Cancer
PROTAC IRAK3 degrader-1 is a potent and selective *IRAK3* degrader with a DC₅₀ of 0.002 μM. PROTAC IRAK3 degrader-1 induces proteasome-dependent degradation of *IRAK3* via ternary complex formation with *IRAK3* and CRBN. PROTAC IRAK3 degrader-1 can be used for cancer research .

HY-168611

PROTAC IRAK4 ligand-4	Ligands for Target Protein for PROTAC IRAK	Cancer
PROTAC IRAK4 ligand-4 is a Ligand for Target Protein for PROTAC with antitumor activity. PROTAC IRAK4 ligand-4 can be used to synthesize PROTAC IRAK4 degrader-12 (HY-168586) .

HY-148275

KTX-955	PROTACs IRAK	Cancer
KTX-955 is an antumor and effective *IRAK4* degrader, with DC₅₀ values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively . KTX-955 is composed of CRBN ligand (blue part) Pomalidomide (HY-10984) and target protein ligand (red part) IRAK4-IN-20 (HY-150735).

HY-129968

AM-Imidazole-PA-Boc	PROTAC Linkers	Cancer
AM-Imidazole-PA-Boc is an alkyl chain-based PROTAC linker can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966) .

HY-W093067

KTX-582 intermediate-4	Drug Intermediate Apoptosis	Cancer
KTX-582 intermediate-4 (intermediate 2-1) is a intermediate to synthesis the *IRAK4* degrader KTX-582 (HY-148274). KTX-582 is also an apoptosis inducer .

HY-49436

KTX-582 intermediate-1	Apoptosis	Cancer
KTX-582 intermediate-1 is an intermediate in the synthesis of KTX-582 (HY-148274) and can be used for ADC preparation. KTX-582 is an IRAK4 degrader and inducer of apoptosis with DC_{50_{of 4 nM and 5 nM for IRAK4 and Ikaros, respectively ^{[1] ^.}}}

HY-49432

KTX-582 intermediate-2	Apoptosis	Cancer
KTX-582 intermediate-2 is an intermediate in the synthesis of KTX-582 (HY-148274) and can be used for ADC preparation. KTX-582 is an IRAK4 degrader and inducer of apoptosis with DC_{50_{of 4 nM and 5 nM for IRAK4 and Ikaros, respectively ^{[1] ^.}}}

HY-49435

KTX-582 intermediate-3	Apoptosis	Cancer
KTX-582 intermediate-3 is an intermediate in the synthesis of KTX-582 (HY-148274) and can be used for ADC preparation. KTX-582 is an IRAK4 degrader and inducer of apoptosis with DC₅₀ of 4 nM and 5 nM for IRAK4 and Ikaros, respectively .

HY-W733885

E3 ligase Ligand 38	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 38 serves as the E3 ligase ligand for PROTAC IRAK4 degrader-12 (HY-168586) and can be used in the synthesis of PROTACs.

HY-183800

JH-l-25-NH2	Ligands for Target Protein for PROTAC IRAK	Inflammation/Immunology
JH-l-25-NH2 is an *IRAK1/4* inhibitor analog derived from JH-I-25 and serves as the *IRAK4*-binding moiety for synthesizing VHL-recruiting and CRBN-recruiting *IRAK4* PROTAC degraders .

HY-162538

LC-MI-3	NF-κB IRAK PROTACs	Inflammation/Immunology
LC-MI-3 is an orally active and potent interleukin-1 receptor-associated kinase 4 (IRAK4) PROTAC degrader, with a DC₅₀ of 47.3 nM. LC-MI-3 effectively inhibits the activation of downstream NF-κB signaling. LC-MI-3 can be used for the research of acute and chronic inflammatory skin. (Blue: VHL ligand, Black: linker, Pink: CRBN ligand (HY-14658)) .

HY-183799

GSI526	PROTACs IRAK NF-κB p38 MAPK	Inflammation/Immunology
GSI526 is a *IRAK4* PROTAC degrader (DC₅₀=40.17 nM, D_max=97%; THP-1) based on the VHL ubiquitin-proteasome system. GSI526 inhibits *IRAK4*-mediated NF-κB and MAPK inflammatory signaling pathways, and induces *IRAK4* degradation in myeloid cells. GSI526 is applicable to inflammation-related research .

HY-B1829R

Dexamethasone phosphate (Standard) Dexamethasone 21-phosphate (Standard)	Glucocorticoid Receptor Reference Standards TGF-β Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
Dexamethasone phosphate (Standard) (Dexamethasone 21-phosphate (Standard)) is the analytical standard of Dexamethasone phosphate (HY-B1829). This product is intended for research and analytical applications. Dexamethasone phosphate (Dexamethasone 21-phosphate) is a prodrug form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone phosphate is prepared by introducing a phosphate ester group to the hydroxyl group at position 21 of the Dexamethasone molecule. Dexamethasone phosphate inhibits LPS (HY-D1056)-induced degradation of IRAK-1 and IRAK-4, and blocks LPS-induced activation of TRAF6, p-TAK1 and p-JNK. Dexamethasone phosphate inhibits the secretion of RANTES, TGF-β1 and NO, promotes the production of MIP-1α and IL-10, and blocks microglial migration. Dexamethasone phosphate is almost completely converted to Dexamethasone in rat blood, and supports transdermal delivery via iontophoresis. Dexamethasone phosphate can be used in research related to steroid-dependent ulcerative colitis, chemotherapy-induced vomiting, allergic asthma and acute colitis (inflammatory bowel disease).

HY-168612

E3 Ligase Ligand-linker Conjugate 125	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 125 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 125 can be used to synthesize PROTAC IRAK4 degrader-12 (HY-168586) .

Cat. No.	Nom du produit		Classification

HY-145483

KT-474 1 Publications Verification KYM-001; PROTAC IRAK4 degrader-7		PROTAC Synthesis
KT-474 (KYM-001; PROTAC IRAK4 degrader-7) is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL. KT-474 is a click chemistry reagent, containing an alkyne group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing azide groups .

Demande en ligne

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Civilité			Country or Region *
Nom du demandeur *			Nom de l'organisation *
Department *
Adresse e-mail *			Nom du produit *
Cat. No.			Requested quantity *
Numéro de téléphone *
Remarques

Demande en ligne

Inquiry Information

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent: